Vyome Therapeutics Announces Nasdaq Approval for Merger with ReShape Lifesciences

Vyome Therapeutics has announced that Nasdaq has approved its listing under the name Vyome Holdings, Inc. with the trading symbol "HIND". The merger with ReShape Lifesciences is expected to take effect on August 15, 2025. Vyome's focus is on immuno-inflammatory and rare diseases in the US and global markets, with a market potential exceeding $100B. The company's clinical-stage assets are developed over years of work and are focused on major unmet indications in the immuno-inflammatory space.

Vyome Therapeutics, Inc. has received approval from Nasdaq to list under the name Vyome Holdings, Inc., with the trading symbol "HIND". The merger with ReShape Lifesciences is expected to take effect on August 15, 2025 [1]. Vyome Therapeutics focuses on developing innovative solutions for immuno-inflammatory and rare diseases in the US and global markets, with a market potential exceeding $100 billion. The company's clinical-stage assets are developed over years of research and are targeted at major unmet indications in the immuno-inflammatory space.

The new board of directors for Vyome Holdings, Inc., includes four MIT alums with extensive experience in board and executive management roles. The board members are aligned with shareholders and are based in the US while having deep ties to the Indian subcontinent and advanced AI technologies [1]. The board will be led by Krishna Gupta, an MIT engineering/business alum and CEO of Remus Capital, who has a strong focus on vertical AI applications in healthcare. Shiladitya Sengupta, a MIT postgrad and serial entrepreneur, will serve as the founder. Venkat Nelabhotla, an IIM Ahmedabad alum with over 30 years of experience in pharma, biotech, and CPG industries, will be the co-founder and CEO. Mohanjit Jolly, a MIT alum and partner at Iron Pillar, will act as a shareholder. John Tincoff, a Georgetown alum and partner at Remus Capital, will also be a shareholder. Stash Pomichter, an MIT engineering dropout and member of the Remus Capital team, will complete the board [1].

Vyome Therapeutics aims to leverage its unique positioning across the US-India innovation corridor to deliver lasting value to shareholders while upholding global standards of quality and safety. The company is based in Cambridge, MA, and has announced its intent to be listed on the Nasdaq exchange under the ticker ‘HIND’ pursuant to a reverse merger with ReShape Lifesciences Inc. (Nasdaq: RSLS) in early 2025 [1].

References:
[1] https://www.biospace.com/press-releases/vyome-announces-new-board-of-directors-with-deep-mit-and-ai-ties